… Moreover, afatinib could be a promising effective single chemotherapy for recurrent/metastatic
HNSCCs; however, further RCTs should be conducted to collect extra survival data …

… Their conclusion was consistent with our finding that afatinib was a cost-effective option [15].
Pignata et al. also found that the base case findings were stable under variation of a range …

… kinase inhibitor (TKI) afatinib in patients with advanced squamous cell carcinoma of the
lung. … No cost-effectiveness data on the use of afatinib as second-line treatment of advanced …

… Afatinib had lower IC 50 values than gefitinib against the same panel. Two … cell lines resistant
to gefitinib were sensitive to afatinib.[Citation16] Both afatinib and cetuximab were effective …

… Cetuximab was not found to have a synergistic effect with afatinib either in vitro or in vivo.
Both afatinib and cetuximab were effective in tumor xenograft model. Afatinib is an effective …

… Compared to adenocarcinoma, fewer effective treatment options are available for advanced
or metastatic squamous cell carcinoma (SCC) of the lung. Afatinib is an orally administered, …

… LUX-Lung 8 was a randomised, controlled, phase 3 study comparing afatinib and erlotinib
as second-line treatment of patients with advanced squamous cell carcinoma (SCC) of the …

… Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer
worldwide [1]. Patients diagnosed with recurrent or metastatic (R/M) disease have a poor …

… There is a major unmet need for effective treatments in patients with squamous cell … that
afatinib has clinical efficacy as second-line treatment for patients with squamous cell carcinoma …

… effective in suppressing tyrosine kinase activity of both wild-type and activated EGFR or HER2
mutants in lung cancer cell lines; these afatinib-sensitive cancer cell … on afatinib were the …